6533b85bfe1ef96bd12babfc

RESEARCH PRODUCT

Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies

Carlos EzquerRotzel HuertaMar JuanGerardo AguilarJavier ColominaJosé FerreresM. Luisa BlascoMarisa CalabuigNieves CarbonellRafael Ferriols

subject

Adultmedicine.medical_specialtymedicine.drug_classCritical IllnessUrinary systemCephalosporinHemodiafiltrationMicrobial Sensitivity TestsOff-label usemedicine.disease_causeExtracorporealPharmacokineticspolycyclic compoundsmedicineHumansPseudomonas InfectionsPharmacology (medical)Intensive care medicineLetter to the EditorPharmacologyCritically illbusiness.industryPseudomonas aeruginosaPrecursor Cell Lymphoblastic Leukemia-Lymphomabacterial infections and mycosesAnti-Bacterial AgentsCephalosporinsInfectious DiseasesPseudomonas aeruginosaFemaleCeftolozanebusiness

description

Ceftolozane-tazobactam (C/T), a novel fifth-generation cephalosporin/β-lactamase inhibitor combination active against multidrug-resistant (MDR) Pseudomonas aeruginosa, is currently approved by the U.S. Food and Drug Administration (FDA) to treat complicated intra-abdominal and urinary tract

yearjournalcountryeditionlanguage
2019-10-30Antimicrobial Agents and Chemotherapy
https://doi.org/10.1128/aac.01782-19